Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
View Patent ↗The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays. Such improvements are based upon the superior performance of assays comprising a chimeric TSH receptor in the presence of a glucocorticoid including, but not limited to, dexamethasone.
1. A method, comprising:
combining;
i) a cell line comprising a stably transfected recombinant plasmid vector encoding a chimeric human thyrotropin stimulating hormone (TSH) receptor operably linked to a reporter gene which encodes a reporter protein, wherein the TSH receptor comprises a portion of a human TSH receptor protein and a portion of a lutenizing hormone human chorionic gonadotropin receptor, wherein the chimeric human TSH receptor preferentially binds to thyroid stimulating autoantibodies compared to binding to thyroid blocking autoantibodies;
ii) a cell culture medium comprising a Growth Medium; and
iii) a serum sample derived from a patient suspected of having Graves' disease,
wherein said combining is under conditions such that said reporter protein produces a detectable signal upon induction by a TSH receptor-specific stimulating auto-antibody.
2. The method of claim 1 , wherein said method further comprises measuring said detectable signal of said reporter protein, wherein said detectable signal correlates with a clinical activity.
3. The method of claim 1 , wherein said method further comprises measuring said detectable signal of said reporter protein, wherein said detectable signal positively correlates with a clinical severity of Graves' disease.
4. The method of claim 3 , wherein said clinical severity of Graves' disease is assessed on the basis of a symptom selected from the group consisting of diplopia, proptosis, visual acuity, ocular motility, optic neuropathy, and extra-ocular muscle thickness.
5. The method of claim 3 , wherein said clinical severity of Graves' disease is measured on the basis of a NOSPECS score.
6. The method of claim 1 , wherein said method further comprises measuring said detectable signal produced by said reporter protein wherein said detectable signal correlates with Graves' orbitopathy.
7. The method of claim 2 , wherein said clinical activity correlates with the concentration of said thyrotropin stimulating hormone autoantibody.
8. The method of claim 3 , wherein said clinical severity of Graves' disease positively correlates with the concentration of said thyrotropin stimulating hormone autoantibody.
9. The method of claim 8 , wherein said clinical severity of Graves' disease is assessed on the basis of a symptom selected from the group consisting of diplopia, proptosis, visual acuity, ocular motility, optic neuropathy, and extra-ocular muscle thickness.
10. The method of claim 8 , wherein said clinical severity of Graves' disease is measured on the basis of a NOSPECS score.
11. The method of claim 6 , wherein said Graves' orbitopathy correlates with the concentration of said thyrotropin stimulating hormone autoantibody.
12. The method of claim 1 , wherein said cell culture medium contains a glucocorticoid.
13. The method of claim 1 , wherein said reporter protein is luciferase.
14. A method, comprising:
combining:
i) a cell line comprising a stably transfected recombinant plasmid vector encoding a chimeric human thyrotropin stimulating hormone (TSH) receptor operably linked to a reporter gene encoding a reporter protein, wherein the TSH receptor comprises a portion of a human TSH receptor protein and a portion of a lutenizing hormone human chorionic gonadotropin receptor, wherein the chimeric human TSH receptor preferentially binds to thyroid stimulating autoantibodies compared to binding to thyroid blocking autoantibodies;
ii) a cell culture medium comprising a Growth Medium; and
iii) an undiluted serum sample and a diluted serum sample from a patient suspected of having Graves' disease,
wherein said combining is under conditions such that said reporter protein produces a detectable signal upon induction by a TSH receptor-specific stimulating auto-antibody.
15. The method of claim 14 , wherein said method further comprises step c) comparing said detectable signal of said reporter protein from said undiluted serum sample with said detectable signal from said diluted serum sample.
16. The method of claim 15 , wherein said comparing of said detectable signal from said undiluted serum sample with said detectable signal from said diluted serum sample provides a reactivity profile indicative of clinical activity.
17. The method of claim 15 , wherein said comparing of said detectable signal from said undiluted serum sample with said detectable signal from said diluted serum sample provides a reactivity profile indicative of a clinical severity of Graves' disease.
18. The method of claim 15 , wherein said comparing of said detectable signal from said undiluted serum sample with said detectable signal from said diluted serum sample provides a reactivity profile indicative of Graves' orbitopathy.
19. The method of claim 14 , wherein said cell culture medium contains a glucocorticoid.
20. The method of claim 14 , wherein said reporter protein is luciferase.